MindBio Therapeutics Corp.
MBIO
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2,548.11% | 967.74% | -54.66% | -4.71% | -57.70% |
| Depreciation & Amortization | -- | 2.74% | -- | 83.49% | -- |
| Other Operating Expenses | -3.93% | -- | -- | -- | -44.20% |
| Total Operating Expenses | 1,579.96% | 2,447.52% | -61.93% | 20.07% | -53.43% |
| Operating Income | -1,579.96% | -114.96% | -152.16% | -910.84% | 53.43% |
| Income Before Tax | -2,507.26% | -436.66% | -1,271.68% | -857.85% | 75.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2,507.26% | -436.66% | -1,271.68% | -857.85% | 75.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 25.00% | -- | -- | -- | -300.00% |
| Net Income | -2,474.27% | -438.53% | -1,269.90% | -847.13% | 75.04% |
| EBIT | -1,579.96% | -114.96% | -152.16% | -910.84% | 53.43% |
| EBITDA | -- | -- | -142.77% | -319.75% | -- |
| EPS Basic | -666.67% | -1.95% | -1,245.05% | -600.67% | 99.93% |
| Normalized Basic EPS | -600.00% | -37.05% | -290.51% | -596.47% | 99.93% |
| EPS Diluted | -666.67% | -1.95% | -1,245.05% | -600.67% | 99.93% |
| Normalized Diluted EPS | -600.00% | -37.05% | -290.51% | -596.47% | 99.93% |
| Average Basic Shares Outstanding | 211.75% | 428.32% | 2.16% | 34.89% | 39,905.52% |
| Average Diluted Shares Outstanding | 211.75% | 428.32% | 2.16% | 34.89% | 39,905.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |